Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT00805012 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

96

Enrollment

OTHER

Sponsor class

Stopped slow accrual rate

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: docetaxel+CDDP
DRUG: docetaxel+S-1

Sponsor

Seoul National University Hospital

Collaborators

[object Object]